[Asia Economy Reporter Jang Hyowon] Helixmith will attend the ‘2021 Cell & Gene Meeting on the Mesa’ held in the United States for three days starting from the 12th. Following last year, Helixmith has been selected as a presenting company at this year’s conference as well. The presenter, Dr. William K. Schmidt, who is in charge of clinical development, is scheduled to introduce the status of pipeline development and research achievements.
‘Cell & Gene Meeting on the Mesa’ is the top annual conference in the cell and gene therapy industry hosted by the Alliance for Regenerative Medicine (ARM) in the United States. This year’s event will have more than 130 companies sharing achievements in gene therapy, gene editing, tissue engineering, and regenerative medicine technologies through online presentations, and over 3,000 partnership meetings will take place.
Dr. William Schmidt of Helixmith will focus on presenting platform technologies and know-how in the gene therapy field, the excellence of the gene therapy product ‘Engensis (VM202)’, the latest clinical development status, and future clinical development strategies at this event.
Dr. William Schmidt said, “It is an honor to present at the ‘Cell & Gene Meeting on the Mesa,’ the most prestigious event in the gene therapy industry. Since executives from global pharmaceutical and bio companies will attend, we expect various forms of business partnerships, including collaborations. At this conference, I look forward to sharing new technologies and trends for patients without treatment options with bio stakeholders.”
Meanwhile, ‘Engensis (VM202)’, developed by Helixmith, is a plasmid DNA gene therapy expressing the HGF protein. It targets the root causes of neuropathy not simply by managing pain but through angiogenesis and nerve regeneration effects. The U.S. FDA recognized the scientific and clinical results of Engensis (VM202) and designated it as a Regenerative Medicine Advanced Therapy (RMAT) in 2018.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
